AzTrials
AzTrials

Skin FoldNCT06000839

A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology)

A study testing (D0) Intradermal injection - micropapula technique, (D14) Intradermal injection - micropapula technique and (D28) Intradermal injection - micropapula technique in people with Skin Fold and Skin Laxity, run by Suisselle at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The current post-market clinical investigation has been designed to evaluate the efficacy and safety of CELLBOOSTER® Lift, a HA-based product marketed by SUISSELLE SA. For this purpose, healthy subjects with signs of skin aging with mild to moderate wrinkles, skin laxity, dry and dull skin on the face, received a… Read more about this study

Who is it for?
Ages 35 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Skin Fold, Skin Laxity, Skin Texture Disorder
What is being tested?
(D0) Intradermal injection - micropapula technique, (D14) Intradermal injection - micropapula technique and (D28) Intradermal injection - micropapula technique
Could I receive a placebo?
No, everyone receives an active treatment
How many people
41 participants
Where
1 siteFrance
Study dates
7 Oct 2022to 1 Feb 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Caucasian
  • Phototype II to III
  • Subject with signs of cutaneous ageing on the face with mild to moderate wrinkles, skin laxity, dry and dull skin on face.
  • Subject with a skin hydration rate on cheekbones < 60 UA, measured with Corneometer®.
  • Subject looking for an improvement using an aesthetic procedure.
  • Subject willing to abstain from other facial aesthetic procedure in the full face through the entire study duration.
Show all 11Show fewer
  • Subject having given their free, express, and informed consent.
  • Subject psychologically able to understand the information related to the study, and to give their written informed consent.
  • Subject registered with a social security scheme.
  • Female of childbearing potential must use a medically accepted contraceptive method since at least 12 weeks before the beginning of the study and throughout the study.
  • Female subjects of childbearing potential must have a negative pregnancy test at the inclusion.

Who cannot join

  • Pregnant or nursing woman or planning a pregnancy during the study.
  • Woman menopaused from less than 1 year or in perimenopause, without hormonal treatment.
  • Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
  • Subject in a social or sanitary establishment.
  • Subject participating to another research on human beings or being in an exclusion period for a previous study.
  • Subject having received a total of 4.500 euros as compensations for their participation in research involving human beings in the last 12 months, including their participation in the present study.
Show all 37Show fewer
  • Intensive exposure to sunlight or UV-rays within the previous month and/or planning to do so during the study.
  • Subject with a tattoo, a scar, moles or too many hairs or anything on the face which may interfere with the study at the investigator appreciation.
  • Subject having resorbable filling product (e.g., hyaluronic acid) injections, a laser treatment, an ultrasound-based treatment, a dermabrasion, a deep chemical peeling or other ablative procedure on the face within the past 12 months prior to study start and a facial surgery in the past 2 years
  • Subjects having received botulinum toxin in the face within the 9 previous months.
  • Subject having received mesotherapy products in the face within the 3 previous months.
  • Subject having done a superficial or medium peeling or a superficial scrub on the face within the 2 previous months.
  • Subject using cosmetic products with alpha hydroxy acids (AHA).
  • Subject with subcutaneous retaining structure on the face (meshing, threads, gold strand).
  • Subject having received injections of permanent (e.g., acrylate polymers, silicone, polytetrafluoroethylene) or semi-permanent filling on the face (L Polylactic acid, Calcium Hydroxyapatite...).
  • Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).
  • Subject with unstable weight or planning to do a dietary regime during the study.
  • Subject with a BMI>30.
  • Subject with ongoing and/or uncontrolled and/or recently recovered (<6 months) depression or psychiatric disorders or any other disorder that may pose a health risk to the subject in the study and/or may have an impact on the study assessments.
  • Subject with severe, ongoing and uncontrolled diseases such as malignancy or history of malignancy, type I diabetes, liver failure, renal failure, lung/heart disease, neoplasia, malignant blood disease, tumor, HIV, or other major disease (e.g., systemic fungal infection).
  • Subject with recurrent porphyria, coronary insufficiency, ventricular rhythm disorders, severe hypertension, obstructive cardiomyopathy, hyperthyroidism.
  • Subject with any skin or systemic disease (acute and/or chronic), in the previous year, likely to interfere with the measured parameters or to put the subject to an undue risk.
  • Subject with known history of or suffering from autoimmune disease and/or immune deficiency.
  • Subject with current cutaneous inflammatory or infectious processes (e.g., acne, herpes, mycosis, papilloma, chronic eczema, atopic dermatitis …), abscess, unhealed wound, or a cancerous or precancerous lesion on the face.
  • Subject with multiple allergies, anaphylactic shock history, evolutive allergic pathologies.
  • Subject having history of allergy or hypersensitivity to one of the components of the tested device
  • Subject having history of hypersensitivity to the antiseptic solution, to lidocaine and/or prilocaine or local anesthetics of amide type or one of the excipients of EMLA 5% cream.
  • Subject predisposed to keloids or hypertrophic scarring.
  • Subject with coagulation and/or homeostasis disorders.
  • Subject with pigmentation disorders (vitiligo, melasma,….).
  • Subject under anti-coagulant treatment (such as aspirin, nonsteroidal anti-inflammatory drugs) or treatment liable to interfere with the healing process or hemostasis, during the previous month and during the study.
  • Subject receiving any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject to undue risk.
  • Subject undergoing a topical (on the face) or systemic treatment:
  • anti-inflammatory medication during the previous 2 weeks and during the study;
  • anti-histaminics during the previous 3 days;
  • immunosuppressors and/or corticoids during the 4 previous weeks and during the study;
  • retinoids during the 6 previous months and during the study.

Trial locations and contacts

1 site in 1 country.

France1 site
  • Eurofins Dermscan

    Villeurbanne

Other trials in France

About this study

Official title: A Prospective, Open Study on the Safety and Effectiveness of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology) on Healthy Subjects

The current post-market clinical investigation has been designed to evaluate the efficacy and safety of CELLBOOSTER® Lift, a HA-based product marketed by SUISSELLE SA. For this purpose, healthy subjects with signs of skin aging with mild to moderate wrinkles, skin laxity, dry and dull skin on the face, received a 3-session treatment and were followed-up over a 4-month period after the initial injection.

Several objective measurements of skin quality were performed with different parameters: skin elasticity, density, dryness, microcirculation, wrinkles, color/homogeneity. Clinical improvement was also evaluated, as well as subject and investigator satisfactions.

The safety of the injections was also followed with injection site reactions and adverse events collection.

Read the detailed description

With age and UV exposure, skin undergoes morphologic and mechanical changes that manifest as wrinkling, sagging, loss of elasticity and dryness. In particular, decreased synthesis of collagen and elastin and their increased degradation reduced proliferative capacity of fibroblasts. Moreover, the perturbations in the organisation of elastic fibre network lead to alterations in the mechanical properties of the skin with reduced resilience and elasticity. Advances in the knowledge of the biochemical mechanisms associated with ageing have led to the development of different approaches to reduce and repair its untoward effects, particularly by using minimally invasive procedures. Originally developed to treat vascular and lymphatic disorders, mesotherapy has recently been used for skin rejuvenation.

Mesotherapy consists of the stimulation of skin biorejuvenation via minimally invasive epidermis or intradermal injections of biologically active substances. The injected ingredients are released over a prolonged period of time into the surrounding tissues, with a depot-like effect. Among the products available for skin rejuvenation by mesotherapy, hyaluronic acid (HA) plays an important role in the moisturization due to its high ability to attract water molecules. Given all the above, HA was a clear natural candidate for such applications, and non-crosslinked HA gels are by far the most popular compounds employed for mesotherapy, both alone and in combination with other molecules. Mesotherapy with HA aids in restoring cutaneous metabolic function, water retention and elasticity, with an altogether improvement in the visible signs of photoaging. The efficacy of non-crosslinked HA injections for the treatment of photoaged skin has been widely reported.

HA-based injections may be supplemented with other active ingredients for additional, synergistic benefits, on condition the compounds be biocompatible and absorbable, such as vitamins, antioxidants and/or amino acids.

Clinical experience of skin rejuvenation by HA-based mesotherapy suggests this technique is safe inasmuch as it is performed by a trained physician, who follows safe-injection practices with appropriate aseptic techniques to prevent, among other, the risk of infection related to inadequate safety measures. Furthermore, several studies suggest mesotherapy can improve skin hydration, firmness and viscoelastic properties. Usually, this type of treatment includes an intensive course with 3 treatments with 2-3 weeks interval, followed by a support course with one treatment per month. The number of treatments needed will depend on the patients (age, skin condition, answer to initial treatment,….).

SUISSELLE has marketed in 2021 the HA-based product CELLBOOSTER® Lift (CBL). CBL consists in a stabilized HA complex with amino acids and vitamins for injection in the epidermis or dermis.

The current post-market clinical investigation is designed to evaluate the efficacy and safety of CBL. For this purpose, healthy subjects with signs of skin aging with mild to moderate wrinkles, skin laxity, dry and dull skin on the face, received a 3-session treatment and were followed-up over a 4-month period after the initial injection.

Several objective measurements of skin quality were performed with different parameters: skin elasticity, density, dryness, microcirculation, wrinkles, color/homogeneity. Clinical improvement was also evaluated, as well as subject and investigator satisfactions.

The safety of the injections was also followed with injection site reactions and adverse events collection.

Being tested
(D0) Intradermal injection - micropapula technique, (D14) Intradermal injection - micropapula technique, (D28) Intradermal injection - micropapula technique
Keywords
Skin Fold, Skin Laxity, Skin Depression, Skin Texture Disorder, Skin Dehydration, Skin Dryness, Skin Quality, Microvascular Circulation, Hyperpigmentation, Oxidative Stress, Atrophic Scar, Striae Distensae, Acne Scars - Mixed Atrophic and Hypertrophic, Epidermis, Dermis, Aesthetic Effect, Aesthetic, Face Treatment, Injection, Micro Papula
Medical subject headings
Cutis Laxa, Hyperpigmentation, Striae Distensae, Hypertrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • (D0) Intradermal injection - micropapula techniqueDevice

    First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)

  • (D14) Intradermal injection - micropapula techniqueDevice

    Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)

  • (D28) Intradermal injection - micropapula techniqueDevice

    Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)

Study groups in NCT06000839
Study groupRoleWhat they receive
CELLBOOSTER® LiftExperimentalNot described
Receives: Device: (D0) Intradermal injection - micropapula technique; Device: (D14) Intradermal injection - micropapula technique; Device: (D28) Intradermal injection - micropapula technique

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline of epidermis hydration higher than 2 AU

    Measured with a Corneometer®

    Measured: Baseline, Day 42

Secondary outcomes (13)
  1. Change from baseline of epidermis hydration

    Measured with a Corneometer®

    Measured: Baseline, Day 84

  2. Change from baseline of cutaneous firmness

    Based on the skin deformation curve obtained with a Cutometer®, the cutaneous firmness, or final deformation (Uf, in mm), is the maximal amplitude of the deformation

    Measured: Baseline, Day 42 and Day 84

  3. Change from baseline of the elasticity

    Based on the skin deformation curve obtained with a Cutometer®, the elasticity is the ratio between various elongation amplitudes (Ur/Ue, Uv/Ue, Ua/Uf)

    Measured: Baseline, Day 42 and Day 84

  4. Change from baseline of the tonicity

    Based on the skin deformation curve obtained with a Cutometer®, the tonicity, or elastic return (Ur, in mm) is the immediate retractation of the skin after the suction

    Measured: Baseline, Day 42 and Day 84

  5. Change from baseline of the suppleness

    Based on the skin deformation curve obtained with a Cutometer®, the suppleness (Ue, in mm) is the immediate elongation of the skin during the suction

    Measured: Baseline, Day 42 and Day 84

  6. Change from baseline of skin density

    Measured with Dermascan®

    Measured: Baseline, Day 42 and Day 84

  7. Change from baseline of skin microcirculation

    Measured with Laser Doppler

    Measured: Baseline, Day 42 and Day 84

  8. Change from baseline of skin wrinkles parameters

    Measured with a fringe projection system

    Measured: Baseline, Day 42 and Day 84

  9. Change from baseline of skin color parameters

    Measured on 2D photographies

    Measured: Baseline, Day 42 and Day 84

  10. Percentage of subjects with a GAIS score "improved", "much improved", or "very much improved" (investigator)

    The Global Aesthetic Improvement Scale (GAIS) is a five-point scale for assessing global aesthetic improvement in appearance compared to pretreatment. This change has been assessed by the investigator.

    Measured: Baseline, Day 42 and Day 84

  11. Percentage of subjects with a GAIS score "improved", "much improved", or "very much improved" (subjects)

    The Global Aesthetic Improvement Scale (GAIS) is a five-point scale for assessing global aesthetic improvement in appearance compared to pretreatment. This change has been assessed by the subjects.

    Measured: Baseline, Day 42 and Day 84

  12. Degree of satisfaction of the subjects

    Satisfaction assessed through the answers to a subjective evaluation questionnaire.

    Measured: Baseline, Day 42 and Day 84

  13. Degree of satisfaction of the injectors

    Satisfaction assessed through the answers to a subjective evaluation questionnaire completed for each subjects after injection. Satisfaction assessed on a scale from "Very dissatisfied" to "Very satisfied".

    Measured: After each injection (Day 0, Day 14 and Day 28)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2023
  2. Study start7 Oct 2022
  3. Primary completion1 Feb 2023
  4. Study completion1 Feb 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
41 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06000839
Sponsor's protocol ID
21E4451
Status last verified
Aug 2023
First submitted
8 May 2023
Last updated
21 Aug 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing (D0) Intradermal injection - micropapula technique, (D14) Intradermal injection - micropapula technique and (D28) Intradermal injection - micropapula technique in people with Skin Fold and Skin Laxity, run by Suisselle at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline of epidermis hydration higher than 2 AU (time frame: Baseline, Day 42). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in